30 April 2013
EMA/223731/2013
Press Office

Public statement

Ribavirin BioPartners (ribavirin)

Expiry of the marketing authorisation in the European Union

On 09 April 2010, the European Commission (EC) issued a marketing authorisation valid throughout the European Union (EU) for the medicinal product Ribavirin BioPartners (ribavirin), indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents. The Marketing Authorisation Holder (MAH) responsible for Ribavirin BioPartners was BioPartners GmbH.

Ribavirin BioPartners has not been marketed anywhere in the EU since the granting of the marketing authorisation. As the product has not been marketed for three consecutive years, in accordance with Article 14(4) of Regulation (EC) N° 726/2004 ("Sunset Clause"), the marketing authorisation of Ribavirin BioPartners has ceased to be valid. BioPartners GmbH was notified accordingly by letter dated 09 April 2013.

The European Public Assessment Report for Ribavirin BioPartners will be updated to reflect that the marketing authorisation is no longer valid.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8427 **Facsimile** +44 (0)20 7418 8409
E-mail press@ema.europa.eu **Website** www.ema.europa.eu